EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score

Abstract

Background and study aims In borderline resectable/locally advanced pancreatic ductal adenocarcinoma (PDAC), stereotactic body radiation therapy (SBRT) is an emerging neoadjuvant treatment option. Endoscopic ultrasound (EUS)-guided insertion of fiducial markers being a prerequisite, our aim was to assess its feasibility and safety and also to evaluate its success, from both the endoscopist’s and radiotherapist’s perspectives.

Patients and methods We prospectively collected data concerning PDAC patients submitted to EUS-guided fiducial placement, from February 2018 to November 2019. Technical success was defined as at least one marker presumed inside the tumor. Quality success was assessed at pre-SBRT computed tomography, accordingly to the number of markers inside or < 1 cm from the tumor, number of markers at the tumor extremity, their location in different planes, the distance between them, and their distance from the biliary stent (if present). A new quality score was then proposed and high-quality success defined as at least six of 12 points.

Results Thirty-seven patients were enrolled. A total of 97 fiducials were implanted, with a median of three fiducials per patient (0–4). The technical success rate was 92 %, with failure of fiducial placement in three patients. Three patients (8 %) had adverse events (fever, mild acute pancreatitis, and biliary stent migration). At pre-SBRT evaluation, two patients’ markers had migrated. The high-quality success rate was 62.5 %.

Conclusions Our results contribute to demonstrating the feasibility and safety of EUS-guided fiducial placement for SBRT treatment in PDAC. It is hoped that the newly proposed quality score will pave the way for improving fiducial positioning and SBRT delivery.

Publication History

Article published online:
03 February 2021

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34
• 2 Maisonneuve P. Epidemiology and burden of pancreatic cancer. Presse Médicale 2019; 48: e113-e123
• 3 Ducreux M, Cuhna AS, Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v56-v68
• 4 Moningi S, Marciscano AE, Rosati LM. et al. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther 2014; 14: 1461-1475
• 5 Herman JM, Chang DT, Goodman KA. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma: SBRT for Unresectable Pancreatic Cancer. Cancer 2015; 121: 1128-1137
• 6 Bouchart C, Navez J, Closset J. et al. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. Ther Adv Med Oncol 2020; 12
• 7 Pishvaian AC, Collins B, Gagnon G. et al. EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. Gastrointest Endosc 2006; 64: 412-417
• 8 Wani S, Han S, Simon V. et al. Setting minimum standards for training in EUS and ERCP: results from a prospective multicenter study evaluating learning curves and competence among advanced endoscopy trainees. Gastrointest Endosc 2019; 89: 1160-1168.e9
• 9 Banks PA, Bollen TL, Dervenis C. et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111
• 10 Coronel E, Cazacu IM, Sakuraba A. et al. EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. Gastrointest Endosc 2019; 89: 659-670.e18
• 11 Chandnani M, Faisal MF, Glissen-Brown J. et al. EUS-guided fiducial placement for pancreatobiliary malignancies: safety, infection risk, and use of peri-procedural antibiotics. Endosc Int Open 2020; 08: E179-E185
• 12 Olender D. Fiducials for target localization. CyberKnife Radiosurgery Pract. Guide. Heilbrun MP. Sunnyvale (CA): CyberKnife Society; 2003
• 13 Goldstein SD, Ford EC, Duhon M. et al. Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol 2010; 76: 597-602
• 14 Dhadham G, Hoffe S, Harris C. et al. Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility. Endosc Int Open 2016; 04: E378-E382